Peregrine Pharmaceuticals appoints Mark R. Bamforth to boards
October 20, 2017, Tustin, Ca., USA - Peregrine Pharmaceuticals appoints Mark R. Bamforth as an independent member of the board of directors of both Peregrine and Avid Bioservices, the company’s wholly-owned contract development and manufacturing organization (CDMO) subsidiary.Additionally, Mr. Bamforth served for more than 20 years in key roles at Genzyme Corporation, including 10 years as a corporate officer responsible for running global manufacturing.
Mr. Bamforth currently serves as the president and CEO of Brammer Bio, a cell and gene therapy CDMO that he founded in 2015 and merged with Florida Biologix, an established, 10-year old CDMO, in March 2016.
Previously, he founded Gallus BioPharmaceuticals, a biologics CDMO that experienced rapid growth leading to its acquisition by DPx Holdings B.V., the parent company of Patheon, in 2014.
Prior to his founding of Brammer Bio and Gallus BioPharmaceuticals, Mr. Bamforth spent 22 years with Genzyme Corporation rising to the position of senior vice president of corporate operations and pharmaceuticals.
While at Genzyme, he served as a member of the CEO’s operating committee, helping to guide corporate strategy acquisition, partnering and growth.
Mr. Bamforth also serves on the boards of MassBio and the Wentworth Institute of Technology, and is a Saltire Foundation founding-trustee.
Mr. Bamforth earned a bachelor of science in chemical engineering from Strathclyde University and an MBA from Henley Management College. ■
